Table 4. Self-reported treatments for test positives, IPTp for malaria, and haematinic supplementation given at first visit ANC among 480 interviewed women.
| Proportion | Success threshold | Target reached for correct ANC strategies? * | |
|---|---|---|---|
| HIV treatment | |||
| Given CTX | 19/29 (65.5%) | ≥90% | Under-reached |
| Given ARVs | 14/29 (48.3%) | ≥90% | Very under-reached |
| Syphilis treatment | |||
| Given 2.4 MU benzathine penicillin or erythromycin | 12/17 (70.6%) | ≥90% | Under-reached |
| Malaria intermittent preventive therapy and treatment | |||
| Given SP for IPTp among women in 2nd trimester not on CTX† | 69/359 (19.2%) | ≥90% | Severely under-reached |
| Given SP for IPTp among women in 1st trimester not on CTX† | 5/41 (12.2%) | ||
| Given SP to women also on CTX‡ | 2/80 (2.5%) | ||
| Given 5 mg folic acid with SP | 7/76 (9.2%) | ||
| Given AL, DP or quinine among malaria positives in 2nd trimester | 121/153 (79.1%) | ≥90% | Under-reached |
| Given quinine among malaria positives in 1st trimester | 2/8 (25%) | ≥90% | Severely under-reached |
| Haematinic supplementation for prophylaxis and treatment | |||
| Given folic acid | 421/480 (87.7%) | ≥90% | Under-reached |
| - Told to take between 0.4–1.2 mg daily | 378/421 (89.8%) | ||
| - Told to take between 5–10 mg daily | 43/421 (10%) | ||
| Given iron | 434/480 (90.4%) | ≥90% | Reached |
| - Given iron and mentioned side effects | 41/434 (9.4%) | ≥90% | Severely under-reached |
| Iron dosing information given to women according to Hb level | |||
| Normal Hb ≥10 g/dL | n = 286 | ||
| - 60–65 mg elemental iron daily | 193/286 (67.4%) | ≥90% | Under-reached |
| - 120–130 mg elemental iron daily | 4/286 (1.4%) | ||
| - 180–195 mg elemental iron daily | 49/286 (17.1%) | ||
| - Not told dosing | 12/286 (4.2%) | ||
| - Not given any iron | 28/286 (9.8%) | ||
| Mild anaemia Hb 8–9.9 g/dL | n = 137 | ||
| - 60–65 mg elemental iron daily | 86/137 (62.8%) | ||
| - 120–130 mg elemental iron daily | 4/137 (2.9%) | ≥90% | Severely under-reached |
| - 180–195 mg elemental iron daily | 32/137 (23.4%) | ||
| - Not told dosing | 3/137 (2.2%) | ||
| - Not given any iron | 12/137 (8.8%) | ||
| Moderate anaemia Hb 5–7.9 g/dL | n = 45 | ||
| - 60–65 mg elemental iron daily | 20/45 (44.4%) | ||
| - 120–130 mg elemental iron daily | 9/45 (20%) | ≥90% | Severely under-reached |
| - 180–195 mg elemental iron daily | 9/45 (20%) | ||
| - Not told dosing | 2/45 (4.4%) | ||
| - Not given any iron | 5/45 (11.1%) | ||
| No Hb recorded | n = 12 | ||
| - 60–65 mg elemental iron daily | 8/12 (66.7%) | ||
| - 120–130 mg elemental iron daily | 1/12 (8.3%) | ||
| - Not told dosing | 2/12 (16.7%) | ||
| - Not given any iron | 1/12 (8.3%) |
* ≥90% target reached, <90% to ≥60—under-reached, <60% to ≥40 very under-reached, <40% severely under-reached
IPTp: intermittent preventive therapy in pregnancy; ANC: antenatal care; CTX: cotrimoxazole; ARV: antiretroviral; SP:sulfadoxine-pyrimethamine; AL: artemether/lumefantrine; DP: dihydroartemisinin-piperaquine (DP); Hb: haemoglobin concentration
†not on CTX includes women who were tested HIV negative, unknown status, and new positive but were not given CTX same day
‡on CTX includes known HIV positives and new HIV positives who were given CTX same day